8-K: Akebia Therapeutics Secures $55 Million Loan Facility with Kreos Capital, Refinances Existing Debt

Akebia Therapeutics has entered into a new $55 million term loan facility with Kreos Capital, which includes an initial $37 million tranche and the refinancing of its previous debt with Pharmakon.

Summary

• Akebia Therapeutics secured a term loan facility of up to $55 million with Kreos Capital.
• The initial tranche of $37 million was funded on January 29, 2024.
• An additional $8 million and $10 million are available in two further tranches, subject to certain conditions, including FDA approval for vadadustat.
• The loan has an initial maturity date of March 31, 2025, which can be extended to January 29, 2028, if vadadustat receives FDA approval by June 30, 2024.
• The company received net proceeds of approximately $34.5 million from the initial loan after deducting fees and expenses.
• The new loan was used to repay the company's previous term loan from Pharmakon.
• The loan accrues interest at a floating rate based on SOFR plus a margin, with a cap of 15% per annum.
• Akebia issued warrants to Kreos to purchase 3,076,923 shares at $1.30 per share, with an additional 1,153,846 shares if the Tranche C loan is drawn.
• The loan is secured by a first priority security interest in substantially all of the company's assets.

Sentiment

Score: 4

Explanation: The document indicates a necessary but potentially risky financing move. The high interest rate, the need for FDA approval to avoid accelerated repayment, and the issuance of warrants are all negative factors. The company is in a difficult position and the financing is a necessary step but not a positive one.

Positives

• The new loan facility provides Akebia with $55 million in potential funding.
• The initial $37 million tranche provides immediate capital.
• The loan refinances existing debt with Pharmakon, simplifying the company's financial structure.
• The maturity date can be extended to 2028 if vadadustat receives FDA approval, providing long-term financial flexibility.
• The interest-only period extends to December 31, 2025, or potentially December 31, 2026, reducing near-term cash outflow.

Negatives

• The loan is secured by a first priority security interest in substantially all of the company's assets.
• The interest rate is variable and could increase, with a cap of 15% per annum.
• The company must meet certain financial covenants, including maintaining a minimum cash balance or revenue target.
• Failure to obtain FDA approval for vadadustat by June 30, 2024, will accelerate the repayment schedule.
• The company issued warrants to Kreos, which could dilute existing shareholders.

Risks

• Failure to obtain FDA approval for vadadustat by June 30, 2024, will result in an accelerated repayment schedule and a shorter interest-only period.
• The variable interest rate could increase, impacting the company's cash flow.
• The company must meet financial covenants, including maintaining a minimum cash balance or revenue target, which could restrict operations.
• The warrants issued to Kreos could dilute existing shareholders.
• The loan is secured by substantially all of the company's assets, increasing the risk in case of default.

Future Outlook

The company's future financial stability is heavily dependent on receiving FDA approval for vadadustat by June 30, 2024, which would extend the loan maturity and provide access to additional tranches of funding. Failure to achieve this will result in an accelerated repayment schedule.

Management Comments

• The document does not contain any direct quotes from management.

Industry Context

This financing is typical for a biotech company in Akebia's stage, seeking to fund operations and development while awaiting regulatory approvals. The reliance on a key regulatory milestone (vadadustat FDA approval) for favorable loan terms is common in the industry.

Comparison to Industry Standards

• The interest rate on the loan, capped at 15%, is within the typical range for venture debt financing for biotech companies, although the SOFR plus 6.75% margin is on the higher end.
• The use of warrants as part of the financing package is a common practice in the biotech industry, providing lenders with potential upside.
• The loan terms, including the extension of the maturity date upon FDA approval, are structured to align the lender's interests with the company's success in obtaining regulatory approval.
• Comparable companies in the biotech space often use similar financing structures, including term loans with warrants, to fund their operations and clinical trials. For example, companies like FibroGen and Global Blood Therapeutics have used similar debt financing structures.

Stakeholder Impact

• Shareholders face potential dilution from the warrants issued to Kreos.
• Creditors are now secured by a first priority security interest in substantially all of the company's assets.
• Employees' job security is tied to the company's ability to meet its financial obligations and obtain FDA approval for vadadustat.

Next Steps

• Akebia needs to secure FDA approval for vadadustat by June 30, 2024, to extend the loan maturity and access additional funding.
• The company must meet the financial covenants outlined in the loan agreement.
• The company may draw down the Tranche B and Tranche C loans by December 31, 2024, if conditions are met.

Key Dates

Keywords

Term Loan Facility, Kreos Capital, Vadadustat, FDA Approval, Debt Financing, Warrants, Refinancing, SOFR, Pharmakon, Financial Covenants